GU Ventures portfolio firm OnDosis partners with Adare Pharma Solutions to advance U.S. ADHD program

• GU Ventures portfolio company OnDosis entered a strategic collaboration with Adare Pharma Solutions to advance its lead U.S. ADHD program.
• Deal targets U.S. commercial manufacturing capability, supporting planned bioequivalence studies and a future regulatory filing for Imfocy.
• OnDosis develops a handheld Dosage Manager device for individualized oral-drug dosing; GU Ventures remains a shareholder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.